Answers are grounded in this paper and cite their sources.
The results of a Phase I clinical trial in which a glypican-3 (GPC3)-derived peptide was tested in advanced hepatocellular carcinoma patients point to a strong correlation between immunological and clinical responses. This commentary reviews our fundamental studies and clinical trials on the GPC3-derived peptide vaccine.
No takes yet. Share an insight, caveat, or question.
Sawada et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: